Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2/3 1

Status

Recruiting 4Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 3Thoracic 1

Conditions

Glioblastoma 2Recurrence 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 550Specimen Handling 462Carboplatin 441Magnetic Resonance Spectroscopy 429Cyclophosphamide 412Cisplatin 398Radiotherapy 313Gemcitabine 310Bevacizumab 306Paclitaxel 294Biopsy 259Drug Therapy 248Capecitabine 241Oxaliplatin 239fludarabine 238Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 202Dexamethasone 186Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 145durvalumab 143Leucovorin 138atezolizumab 137toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Interventional × AZD1390 × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

Phase 1 Recruiting
54 enrolled
CNS

Astrocytoma

NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT04550104 2025-12-19

CONCORDE

University of Leeds

Phase 1 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡